Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 2/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639481 | 0.86 | HTR1D (0.48) | MYCRAB9ANPC1KMT2ATSHR | |
| SCHEMBL19639483 | 0.83 | RARA (0.46) | RAB9ANPC1HTR1DRARARARB | |
| SCHEMBL23952927 | 0.80 | NPC1 (0.61) | MYCRAB9ANPC1KMT2ATSHR | |
| SCHEMBL11438341 | 0.76 | NPC1 (0.89) | MYCRAB9ANPC1KMT2ATSHR | |
| SCHEMBL12171906 | 0.75 | NPC1 (0.62) | MYCRAB9ANPC1KMT2ATSHR | |
| SCHEMBL12171816 | 0.75 | NPC1 (0.84) | MYCRAB9ANPC1KMT2ATSHR | |
| SCHEMBL12171344 | 0.74 | NPC1 (0.65) | MYCRAB9ANPC1KMT2ATSHR | |
| SCHEMBL28642603 | 0.74 | NQO2 (0.41) | ALDH1A1RARARARBRARGKDM4E | |
| SCHEMBL12171885 | 0.73 | NPC1 (0.77) | MYCRAB9ANPC1KMT2ATSHR | |
| SCHEMBL19639445 | 0.73 | RARB (0.59) | MYCRAB9ANPC1KMT2ASNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647688-B2 | Compounds, synthesis method thereof and use of same in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-05-12 | — | — | US | claimed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | claimed |
| EP-3233806-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2017-10-25 | — | — | EP | claimed |
| WO-2016097626-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | claimed |
| EP-3233806-B1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RES & DEV (FR) | 2021-10-27 | — | — | EP | disclosed |
| EP-3233806-B1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RES & DEV (FR) | 2021-10-27 | — | — | EP | disclosed |
| US-10647688-B2 | Compounds, synthesis method thereof and use of same in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-05-12 | — | — | US | disclosed |
| US-10647688-B2 | Compounds, synthesis method thereof and use of same in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-05-12 | — | — | US | disclosed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| EP-3233806-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097626-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | RARA, RARB, RARG | MYC 2365/4885RAB9A 2985/4885NPC1 2472/4885 |
| US-10647688-B2 | Compounds, synthesis method thereof and use of same in medicine and in cosmetics | RARA, RARB, RARG | MYC 2200/4885RAB9A 3028/4885NPC1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.